Background: The spleen is the primary reservoir of immune cells in mammals. Diverse stimuli can disrupt spleen homeostasis, resulting in spleen injury and immune dysfunction. This study employed a porcine model to assess the therapeutic potential of salvianolic acid B (SAB) against lipopolysaccharide (LPS)-induced splenic injury. Methods: Seventy-two male weanling piglets were randomly assigned to one of four groups: CON-SS, SAB-SS, CON-LPS, and SAB-LPS. The CON-SS and CON-LPS groups received a basal diet, while SAB-SS and SAB-LPS groups received a SAB-supplemented diet. After 14 d, the CON-SS and SAB-SS groups received an intraperitoneal injection of sterile saline, whereas the CON-LPS and SAB-LPS groups were injected with LPS. Blood and spleen tissues were harvested 6 h post-injection for biochemical analysis. Results: LPS induced systemic immune disorders in piglets, as evidenced by increased immune organ indices and decreased white blood cell, lymphocyte, and basophil counts in blood (p < 0.05). LPS also caused histoarchitectural disruption, cell apoptosis, oxidative stress, and inflammation in the spleen (p < 0.05). Conversely, SAB improved splenic histopathology and reduced splenic apoptosis and pro-inflammatory mediators in piglets (p < 0.05). SAB significantly mitigated peroxidation accumulation by facilitating the nuclear translocation of nuclear factor erythroid 2-related factor 2 and strengthening the antioxidant system, and inhibited nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome activation (p < 0.05). Mechanistically, SAB attenuated LPS-induced splenic oxidative stress and NLRP3 inflammasome activation by restoring mitochondrial structure and function (p < 0.05). Conclusions: This research unveils that SAB alleviates LPS-induced spleen disorder by reinforcing antioxidant system and suppressing NLRP3 inflammasome, highlighting SAB’s potential as a prospective therapeutic agent for spleen disorders.
Background: Intestinal epithelial barrier dysfunction, a major consequence of inflammatory and oxidative stress, contributes to enteric disorder progression. Salvianolic acid B (SAB), a prominent water-soluble phenolic compound in Salvia miltiorrhiza, shows intestinal protective potential, but the underlying mechanisms remain unclear. Methods: This study investigated the protective effects of SAB on intestinal barrier function using a lipopolysaccharide (LPS)-challenged piglet model and LPS-stimulated IPEC-J2 cells. Results: SAB alleviated LPS-induced intestinal injury, evidenced by reduced plasma diamine oxidase and D-lactate levels, improved intestinal morphology, decreased pro-inflammatory cytokines, and enhanced antioxidant capacity. SAB also strengthened intestinal barrier integrity by increasing goblet cell number and mucin 2 levels and upregulating tight junction protein expression. Moreover, SAB restored epithelial proliferation–apoptosis balance and increased PI3K/AKT/mTOR phosphorylation. Molecular docking and molecular dynamics simulations predicted a stable SAB–PI3Kα/p110α interaction, whereas LY294002 treatment attenuated SAB-mediated restoration of epithelial renewal and barrier integrity in LPS-treated IPEC-J2 cells. SAB also altered the jejunal microbial composition, including higher relative abundance of Streptococcus and lower relative abundance of Escherichia-Shigella, together with increased jejunal acetate and lactate concentrations. Conclusions: SAB alleviates inflammation-associated intestinal barrier dysfunction by restoring epithelial proliferation–apoptosis balance and regulating the microbiota–metabolite profile.